# US 2026/0060927 A1 · Liposomal particles, methods of making same and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060927 A1
- Document ID: US20260060927A1
- Status: Published application
- Kind: A1
- Application number: 19/284,280
- Filed: 2025-07-29
- Published: 2026-03-05
- Earliest claimed: 2013-12-03
- Assignees: Northwestern University
- Applicants: Northwestern University
- Inventors: Chad A. MIRKIN; Sonbinh T. NGUYEN; Resham Singh BANGA; Natalia CHERNYAK
- Web page: https://patentgrep.com/patent/US20260060927A1

## CPC

- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/1277: Preparation processes; Proliposomes
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/11: Antisense
- C12N 2310/12: catalytic nucleic acids, e.g. ribozymes
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Liposomes termed as small unilamellar vesicles (SUVs), can be synthesized in the 20-50 nm size range, but encounter challenges such as instability and aggregation leading to inter-particle fusion. This limits their use as a therapeutic delivery agent. Increasing the surface negative charge of SUVs, via the attachment of anionic entities such as DNA/RNA, increases the colloidal stability of these vesicles. Additionally, the dense spherical arrangement and radial orientation of nucleic acids exhibits unique chemical and biological properties, unlike their linear counterparts. These liposomal particles, are non-toxic and though anionic, can efficiently enter cells without the aid of ancillary cationic transfection agents in a non-immunogenic fashion. These exceptional properties allow their use as delivery agents for gene regulation in different therapies and offer an alternative platform to metal core spherical nucleic acids.

## Claims

### Claim 1

A plurality of liposomal particles, each liposomal particle having a substantially spherical geometry and comprising:
a lipid bilayer comprising a plurality of lipid groups, and
a plurality of oligonucleotides on the external side of the lipid bilayer, wherein each oligonucleotide is a toll-like receptor 9 (TLR9) agonist, wherein each oligonucleotide is an oligonucleotide-lipid conjugate containing one lipophilic tethered group, wherein each lipophilic tethered group is adsorbed into the external side of the lipid bilayer, and wherein said plurality of liposomal particles has a mean diameter of less than or equal to about 50 nanometers (nm).

### Claim 2 (depends on 1)

The plurality of liposomal particles of claim 1, wherein said plurality of liposomal particles has a mean diameter of less than 50 nanometers (nm).

### Claim 3 (depends on 2)

The plurality of liposomal particles of claim 2, wherein the mean diameter of said plurality of liposomal particles is less than 45 nanometers (nm).

### Claim 4 (depends on 3)

The plurality of liposomal particles of claim 3, wherein the mean diameter is more than 5 nanometers (nm).

### Claim 5 (depends on 4)

The plurality of liposomal particles of claim 4, wherein the mean diameter is more than 10 nanometers (nm).

### Claim 6 (depends on 1)

The plurality of liposomal particles of claim 1, wherein said plurality of liposomal particles has a mean diameter of between 5 and 50 nanometers (nm).

### Claim 7 (depends on 6)

The plurality of liposomal particles of claim 6, wherein the mean diameter of said plurality of liposomal particles has a mean diameter of between 20 and 45 nanometers (nm).

### Claim 8 (depends on 1)

The plurality of liposomal particles of claim 1, wherein the oligonucleotides on the external side of the lipid bilayer comprise about 10-100 oligonucleotides.

### Claim 9 (depends on 8)

The plurality of liposomal particles of claim 8, wherein the oligonucleotides comprise about 10-60 oligonucleotides.

### Claim 10 (depends on 9)

The plurality of liposomal particles of claim 9, wherein the oligonucleotides comprise about 10-40 oligonucleotides.

### Claim 11 (depends on 9)

The plurality of liposomal particles of claim 9, wherein the oligonucleotides comprise about 50 oligonucleotides.

### Claim 12 (depends on 1)

The plurality of liposomal particles of claim 1, wherein the lipophilic tethered group is at the 3′-end of each oligonucleotide.

### Claim 13 (depends on 1)

The plurality of liposomal particles of claim 1, wherein the lipophilic tethered group is tocopherol or cholesterol.

### Claim 14 (depends on 1)

The plurality of liposomal particles of claim 1, wherein all oligonucleotides are single-stranded.

### Claim 15 (depends on 1)

The plurality of liposomal particles of claim 1, wherein the TLR9 agonist is a CpG-containing oligonucleotide.

### Claim 16 (depends on 15)

The plurality of liposomal particles of claim 15, wherein the CpG-containing oligonucleotide comprises the sequence: 5′-TCGTCGTTTTGTCGTTTTGTCGTT-3′ (SEQ ID NO: 8).

### Claim 17 (depends on 15)

The plurality of liposomal particles of claim 15, wherein said plurality of liposomal particles has a mean diameter of between 5 and 50 nanometers (nm).

### Claim 18 (depends on 16)

The plurality of liposomal particles of claim 16, wherein said plurality of liposomal particles has a mean diameter of between 5 and 50 nanometers (nm).

### Claim 19 (depends on 15)

The plurality of liposomal particles of claim 15, wherein the oligonucleotides comprise about 10-60 oligonucleotides.

### Claim 20 (depends on 16)

The plurality of liposomal particles of claim 16, wherein the oligonucleotides comprise about 10-60 oligonucleotides.
